Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 200.79

-0.2%

Nov 14 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Proton who wrote (18665)	4/5/1998 5:12:00 PM
From: RXGOLF	Read Replies (1) of 32384

<<Tamoxifen has a major clinical study to back up its prevention claims; Targretin does not. Furthermore, Tamoxifen is first past the prevention post>> These are good points Peter. IMHO however, this is not bad news for Ligand. Yes, being first is a plus. Tagamet comes to mind. When it first came to market as the only H2 antagonist they made a bundle. However, I too remember when Zantac came out a bit later as the second H2 antagonist.It, like Tagamet worked well, and had a few advantages. It too made a Bundle!! No. we have no studies to back up prevention and may never. However, speculation is part of what drives the biotechs. I hope that first some will speculate that Targretin may provide prevention. Then I hope that studies will prove that Targretin provides prevention. Then I hope it makes a Bundle! Good Luck, and at least this might be considered on topic (:- ). RXGOLF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next